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Background. Allergy to cat dander is a common form of allergic disease. Allergen immunotherapy has been demonstrated to be
effective in decreasing allergic symptoms. Objectives. To examine outcomes in allergic asthmatic patients on cat immunotherapy
(CIT) compared to allergic asthmatics on traditional immunotherapy (IT) without cat sensitivity.Methods. A retrospective review
identified allergic asthmatics on CIT for at least three years. An equal number of allergic asthmatics on IT were identified
for comparison. Outcomes investigated include measurements of risk of asthma exacerbation. Results. Thirty-five patients were
identified in each group. There were no differences in the CIT group versus the comparison group regarding total number of
prednisone tapers (18 tapers versus 14 tapers, resp.), number of patients requiring prednisone tapers (10 patients versus 10 patients,
resp.), total number of acute visits (29 visits versus 38 visits, resp.), and number of patients requiring acute visits (15 patients versus
21 patients, resp.). When stratified by concomitant ICS use, patients on CIT were less likely to require an acute visit (46% versus
78%, resp.). Conclusions. Allergic asthmatics with cat sensitivity on CIT with close dander exposure have similar risk of asthma
exacerbation compared to allergic asthmatics without cat sensitivity on immunotherapy.
1. Introduction
Allergen injection immunotherapy with cat dander extract
(CIT) is an effective treatment for allergic bronchial asthma in
acute challenge models of cat allergy, but there is limited data
concerning the efficacy of CIT in the clinical setting [1, 2].
Indications for allergen immunotherapy in a patient with
allergic asthma include increased symptoms after exposure to
the allergen demonstrated evidence of clinically relevant spe-
cific IgE antibodies and one of the following: poor response
to pharmacotherapy or allergen avoidance, desire to avoid
long-term pharmacotherapy, or coexisting allergic rhinitis
[3]. Allergy to pets presents unique management issues. The
theoretical opportunity exists for the cat allergic patient to
remove the source of allergen from the home environment.
However patients and their families are emotionally attached
to pets and often resist recommendations to remove them.
A pet cat or cats in the home are associated with high lev-
els of allergen exposure and increases in nonspecific airway
hyperreactivity [4, 5]. While persistent symptoms even with
a change in environment have been demonstrated, there is
little direct evidence to answer the common patient question:
“Is there a way I can safely keep the cat?” [6].
The purpose of the following study is to compare clinical
outcomes of allergic asthmatic patients with cat sensitivity
and close dander exposure on CIT to patients with allergic
asthma on allergen immunotherapy (IT), however, without
cat sensitivity.
2. Materials and Methods
Records reviewed were those of adult allergic asthmatic
patients (18 years or older) undergoing subcutaneous
immunotherapy, based on skin testing and history, for at
least three consecutive years.
This study was a retrospective chart review conducted at a
single urban, university hospital-based allergy, and immunol-
ogy practice. It was approved by the Thomas Jefferson Uni-
versity Institutional Review Board.We evaluated measures of
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clinical outcomes in allergic asthmatic patients on continuous
immunotherapy during the period of January 2005 through
December 2008. Clinical outcomes were assessed during the
second and third years of immunotherapy.
The study group consisted of cat allergic asthmaticpa-
tients as determined by skin prick or intradermal skin test
to Fel d1 (Greer’s Standardized Cat Hair, dose 10,000 bau/mL
and 100 bau/mL respectively) with perennial, usually home,
exposure to cat dander. Skin prick and intradermal testing
results were determined by one of two allergists. Asthma was
defined as a clinical diagnosis made by one of two allergists
documented in the patient’s chart. CITwas administeredwith
standardized cat hair extract according to the manufacturer’s
label (Greer Laboratories).
An equal number of allergic asthmatic patients with no
cat sensitivity on subcutaneous IT during the same time
period were randomly selected to serve as controls. Allergen
extracts for noncat allergens were selected according to
conventional practice, based on skin test results, patient
history, and prevalent regional allergens. All patients avoided
antihistamines at least five days prior to skin testing.
FEV1, a marker of asthma impairment, was recorded in
both groups as well as age, gender, inhaled corticosteroids
(ICS) use, duration of immunotherapy, and previous diagno-
sis of allergic rhinitis.
Outcome variables investigated are markers of risk for an
asthma exacerbation and include the following: prednisone
tapers, acute outpatient visits for asthma-related symptoms,
and hospitalizations for asthma-related symptoms during the
second and third years of immunotherapy. In a subgroup
analysis, patients on concomitant ICS were compared using
the same outcome variables.
Statistical Analysis. Statistical analyses were carried out using
STATA version 10.0 statistical software (Stata Corp, College
Station, TX, USA). Comparisons between groups were made
using the 𝑡-test and 𝜒2 test for continuous and categorical
variables, respectively.
3. Results and Discussion
3.1. Results. A total of 70 patients were included in these
analyses. Thirty-five patients with allergic asthma, peren-
nial cat exposure, positive skin prick or intradermal test
to standardized cat extract, and undergoing subcutaneous
CIT ± other subcutaneous immunotherapy were identified.
An equal number of patients with allergic asthma undergo-
ing subcutaneous IT, but where significant cat allergy and
exposure were not found to be present, were identified as well
and served as the comparison group. As will be discussed in
more detail, and as the demographics confirm, the reasoning
behind this choice was to identify an asthma patient subset of
similar baseline impairment but without cat allergy playing
an important role.
There was no difference in gender or age between the
two groups (Table 1). All patients had a minimum of three
years of immunotherapy and there was no difference in
average duration of immunotherapy between the CIT group
Table 1: Patient characteristics.
Cat
immunotherapy
𝑛 = 35
Other
immunotherapy
𝑛 = 35
𝑃
value
Gender, 𝑛 (%)
Male 14 (40%) 17 (49%)
Female 21 (60%) 18 (51%) 0.47
Age (years)
Mean (SD) 49.3 (14.7) 55 (13.6) 0.11
Range 29–86 28–89
Baseline FEV1 (%)
Mean (SD) 84.4 (21.8) 86.6 (17.9) 0.66
Range 38–117 43–127
History of allergic
rhinitis 34 (97%) 35 (100%) 0.31
Mean duration
immunotherapy
(years) (SD)
5.2 (1.9) 5.5 (2.5) 0.36
Inhaled
corticosteroids 𝑛, (%) 26 (74%) 23 (66%) 0.43
Treatment antigens 𝑛,
(%)
Dog 10 (29%) 9 (26%) 0.79
Pollen 16 (46%) 25 (71%) 0.02
Mold 3 (9%) 15 (43%) 0.001
Dust/mite 20 (57%) 33 (94%) 0.001
Allergic asthmatic patients on cat immunotherapy or traditional immun-
otherapy.
Comparisons between groups were made using the 𝑡 test and 𝜒2 test where
appropriate.
(5.2 years) and the IT group (5.5 years) (𝑃 = 0.36). Percentage
of FEV1 (CIT = 84.4%, IT = 86.6%; 𝑃 = 0.66) and ICS
use prior to initiation of immunotherapy (26 patients in CIT
group versus 23 patients in IT group; 𝑃 = 0.43) was not
significantly different. The prevalence of allergic rhinitis was
similar among patients in both groups (CIT = 97%, IT =
100%; 𝑃 = 0.31).
Patients in the CIT group were significantly less likely
to be receiving subcutaneous pollen (46% versus 71%; 𝑃 =
0.02), mold (9% versus 43%; 𝑃 = 0.001), and dust/mite (57%
versus 94%;𝑃 = 0.001) immunotherapy compared to patients
in the IT group (Table 2). Presumably, this reflected genetic
and/or exposure differences in propensity to sensitization
by these various allergen groups. There was no significant
difference in the number of patients requiring prednisone
tapers (𝑃 = 1.0), total number of prednisone tapers (𝑃 =
0.58), number of patients requiring an acute office visit for
asthma symptoms (𝑃 = 0.15), total number of acute office
visits for asthma symptoms (𝑃 = 0.38), and number of
hospitalizations between the two groups (𝑃 = 0.31).
In a subgroup analysis considering only patients on
concomitant ICS, there were twenty-six patients undergoing
CIT ± other subcutaneous immunotherapy and twenty-
three patients undergoing IT (Table 3). There was no dif-
ference in gender, age, baseline percentage FEV1, duration
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Table 2: Clinical outcomes in patients on CIT and IT.
Cat
immunotherapy
𝑛 = 35
Other
immunotherapy
𝑛 = 35
𝑃
value
Patients requiring
prednisone taper, 𝑛 (%) 10 (29%) 10 (29%) 1.00
Prednisone tapers, 𝑛 18 14 0.58
Patients requiring
acute office visit, 𝑛 (%) 15 (43%) 21 (60%) 0.15
Acute office visits, 𝑛 29 38 0.38
Hospitalizations, 𝑛 (%) 1 (3%) 0 (0%) 0.31
Allergic asthmatic patients on cat immunotherapy or traditional
immunotherapy.
Comparisons between groups were made using the 𝑡 test and 𝜒2 test where
appropriate.
Table 3: Characteristics of patients on inhaled corticosteroids.
Cat
immunotherapy
𝑛 = 26
Traditional
immunotherapy
𝑛 = 23
𝑃
value
Gender, 𝑛 (%)
Male 10 (38%) 10 (43%) 0.72
Female 16 (62%) 13 (57%)
Age (years)
Mean (SD) 49 (13.7) 56 (12.6) 0.05
Range 29–75 36–80
Baseline FEV1 (%)
Mean (SD) 80.8 (21.5) 85.0 (20.4) 0.49
Range 38–112 43–127
History of allergic
rhinitis 25 (96%) 25 (100%) 0.34
Mean duration
immunotherapy (years)
(SD)
5.2 (2.0) 5.7 (2.3) 0.62
Treatment antigens,
𝑛 (%)
Dog 7 (27%) 6 (26%) 0.94
Pollen 11 (42%) 19 (83%) 0.004
Mold 3 (12%) 13 (57%) 0.001
Dust/mite 13 (50%) 22 (96%) 0.001
Allergic asthmatic patients on inhaled corticosteroids and immunotherapy
Comparisons between groups were made using the 𝑡 test and 𝜒2 test where
appropriate.
of immunotherapy, or history of allergic rhinitis. Patients in
the CIT group were less likely to be receiving subcutaneous
pollen (42% versus 83%; 𝑃 = 0.004), mold (12% versus
57%; 𝑃 = 0.001), and dust/mite (50% versus 96%; 𝑃 =
0.001) immunotherapy compared to patients in the IT group.
Unfortunately, our data does not allow us to further elucidate
why; for example, patients symptomatic with cat induced
allergic asthma were less likely to have pollen allergy. This
may be another manifestation of the conflicting data on
the effect of animals in the home on the development of
symptomatic atopy. Patients onCIT and ICSwere less likely to
Table 4: Clinical Outcomes in Patients on Concomitant ICS.
Cat
immunotherapy
𝑛 = 26
Traditional
Immunotherapy
𝑛 = 23
𝑃
value
Patients requiring
prednisone taper, 𝑛 (%) 10 (38.4%) 10 (43%) 0.72
Prednisone tapers 18 14 0.76
Patients requiring acute
office visit, 𝑛 (%) 12 (46%) 18 (78%) 0.02
Acute office visits 26 visits 34 visits 0.21
Hospitalizations, 𝑛 (%) 1 (3.8%) 0 (0%) 0.34
Allergic asthmatic patients on inhaled corticosteroids and immunotherapy.
Comparisons between groups were made using the 𝑡 test and 𝜒2 where
appropriate.
require an acute office visit for asthma symptoms as compared
to patients on IT and ICS (46% versus 78%; 𝑃 = 0.02)
(Table 4).
3.2. Discussion. Allergic asthmatic patients with cat allergy
and perennial exposure to cat dander showed benefit from
CIT. Asthmatic CIT patients on ICS were less likely to
require an acute office visit for asthma-related symptoms
compared to allergic asthmatic patients on IT and concomi-
tant ICS although they had similar baseline characteristics.
An improvement in asthma symptomatology—specifically
improvement in bronchial sensitivity and hyperresponsive-
ness to histamine—in patients on both allergen specific
immunotherapy and concomitant inhaled corticosteroids has
been reported in a pediatric population [7]. To our knowl-
edge, this is the first report comparing clinical outcomes
in adult patients on particular allergen immunotherapy and
concomitant ICS.
There has been a significant amount of data detailing the
immune response to CIT; however, evidence supporting clin-
ical benefit is sparse [8–10]. This study is important because
it demonstrates some improvement in clinical parameters in
patients on CIT and concomitant ICS compared to patients
on IT and concomitant ICS. While this seems inexplicable, it
may reflect another aspect of the proposed protective effect
of animals in the home on atopic disease. That is well beyond
the scope of this report but raises the intriguing question as
to whether cat induced asthma was somehow protective as it
relates to other allergic disease.
This hypothesis would also be supported by the fact
that cat allergic patients were less likely to be receiving
other extracts. Alternatively, thismay reflect antigen selection
based on the most likely antigens to be causing a particular
patient’s symptoms, but it is of interest that the two groups,
so similar in many ways, differed significantly in the other
antigens that were thought clinically significant.
Clinicians are commonly confrontedwith cat ownerswho
are adamantly opposed to eliminating the cat from their
home environment. The persistence of cat allergen com-
plicates management of the cat-sensitive asthmatic patient.
The allergen may be present for several years even after the
cat is displaced from the environment [11, 12]. Preventative
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measures including cat washing, keeping cats outside of
bedrooms and the utilization of air filtration may be of little-
to-no benefit [11, 13–15]. Our data suggest that cat owners
on CIT do equally well as other asthmatic patients also
undergoing immunotherapy, but without cat allergy and
potent cat antigens inside their homes. This suggests that
patients may indeed safely keep their cats, at least if they do
so in association with a course of allergen immunotherapy to
cat antigen.
A key question is whether keeping the cat will result
in long-term, irreversible harm, as seen in other exposure
models [16, 17]. Pulmonary epithelial damage in the asth-
matic patient allows allergen and other toxins to precipitate
in the airway thus augmenting inflammation, leading to
airway remodeling [18]. In mice, chronic exposure to house
dust mite has demonstrated a disturbance of the epithelial-
mesenchymal trophic unit and increased production of
deleterious mesenchymal proteins in the large airway [19].
There is also evidence of increased levels of inflammatory
proteins and upregulation of remodeling genes following
allergen exposure, with persistence of remodeling proteins
for at least seven days [20]. A next investigative step would
be to determine if airway remodeling, a pathophysiologic
process of increasing importance, is inhibited by allergen IT
in patients on appropriate specific IT.
There are limitations to note in this study. The authors
would be remiss if not to report that this study was under-
powered (69%) when considering the significant finding of
asthmatic CIT patients on ICS being more likely to require
an office visit. In addition, patients in the CIT group were less
likely to be on pollen, dust/mite, and mold immunotherapy
compared to the comparison group.While we have suggested
intrinsic differences in the groups, one could suggest that
these groups are therefore not similar in otherways, unrelated
to cat exposure and sensitization. In the authors’ opinion, it is
not the number of antigens selected for immunotherapy that
is indicative of the severity of disease, but rather the decision
to proceed with immunotherapy itself.
Markers of bronchial responsiveness including PC 20
histamine challenges and allergen challenges are frequently
usedwhen evaluating the effect of immunotherapy on asthma
control. This data was not available for our study. However,
our outcome variables were reflective of those commonly
used to assess clinical response. Another limitation to note
concerns selection of participants into the study. Cat allergic
patients may be more motivated to undergo any treatment
that is intended to reduce the likelihood they will need to
eliminate a beloved pet.
Ideally, a randomized, double blind placebo control study
would better elucidate the effect of CIT on cat exposed
sensitized patients. Such a study is unlikely to be undertaken.
Regarding duration of treatment needed, it would require
several years with half the subjects getting placebo. In light
of the availability of subcutaneous immunotherapy and the
data on efficacy in general and CIT specifically, patient
recruitment would be problematic and the expense of such
a study might be difficult to justify.
For this reason we selected a comparison group of similar
symptomatic subjects and similar asthma impairment, but
where cat allergy did not play an important role, and towhom
cat extract was not administered. All subjects were followed
closely. While this was a retrospective review, they were all
seen and evaluated regularly, and the parameters selected
for evaluation were of the type usually well documented in
patient records.
4. Conclusion
We found asthmatic patients with allergy to cat and regular
cat exposure do as well or better on CIT than similarly ill
asthma patients receiving allergen immunotherapy but where
cat allergy is not considered clinically important. While
chronic allergen exposure has been shown to have deleterious
effect, including enhanced airway remodeling, cat allergic
patients treated with specific CIT may be protected from
adverse outcome.
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